Xilio Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company generated total revenue of $12.6 million, a substantial increase from $2.9 million in the same period last year, primarily driven by collaboration and license revenue from agreements with AbbVie and Gilead. Despite this revenue growth, Xilio continued to experience operating losses, reporting a net loss of $9.5 million compared to a loss of $13.3 million in the prior year, reflecting a decrease in losses of $3.7 million.
The company's operating expenses rose to $26.8 million from $16.8 million year-over-year, with research and development costs accounting for $19.8 million, up from $8.3 million. This increase was attributed to heightened manufacturing activities and external expenses related to preclinical research and development. General and administrative expenses decreased to $6.9 million from $8.5 million, primarily due to reduced professional and consulting fees. The overall loss from operations was slightly higher at $14.1 million compared to $13.9 million in the previous year.
In terms of strategic developments, Xilio completed a follow-on offering in February 2026, raising net proceeds of $37.3 million through the issuance of prefunded warrants. The company also achieved a $6.0 million development milestone related to its collaboration with AbbVie in the second quarter of 2026. As of March 31, 2026, Xilio's cash and cash equivalents stood at $150.3 million, which the company anticipates will be sufficient to fund its operations into early 2028, excluding potential additional milestone payments and other contingent revenues.
Operationally, Xilio has made strides in advancing its clinical programs, including the development of masked immuno-oncology therapies. The company reported an increase in its employee headcount, reflecting its commitment to expanding its research capabilities. As of the end of the first quarter, Xilio had 5,782,536 shares of common stock outstanding, a significant increase from 4,530,641 shares at the end of 2025, following the issuance of new shares in connection with its financing activities.
Looking ahead, Xilio expects to continue incurring significant operating losses as it advances its product candidates through clinical trials and maintains the necessary infrastructure for its operations. The company remains focused on its strategic partnerships and the potential for future revenue generation from its collaborations, while also preparing for the challenges associated with drug development and commercialization.
About Xilio Therapeutics, Inc.
Xilio Therapeutics is a biotech company developing tumor-activated immuno-oncology therapies that localize immune responses within the tumor microenvironment to enhance efficacy and reduce systemic toxicity. Its pipeline includes antibody, cytokine, and T cell engager candidates, leveraging proprietary masking platforms. The company focuses on innovative, highly selective treatments for solid tumors, with collaborations and a strong intellectual property portfolio supporting its mission to improve cancer outcomes.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.